Your browser doesn't support javascript.
loading
Baclofen Pump Use: Complications After Growth-friendly Instrumentation for Early-onset Scoliosis.
Xu, Amy L; Marrache, Majd; Hardesty, Christina K; Groves, Mari L; Erickson, Mark A; Murphy, Robert F; Thompson, George H; Sponseller, Paul D.
Afiliación
  • Xu AL; Departments of Orthopaedic Surgery.
  • Marrache M; Departments of Orthopaedic Surgery.
  • Hardesty CK; Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, OH.
  • Groves ML; Neurology and Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD.
  • Erickson MA; Children's Hospital Colorado, Denver, CO.
  • Murphy RF; Department of Orthopaedics and Physical Medicine, Medical University of South Carolina, Charleston, SC.
  • Thompson GH; Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, OH.
  • Sponseller PD; Departments of Orthopaedic Surgery.
J Pediatr Orthop ; 42(2): 77-82, 2022 Feb 01.
Article en En | MEDLINE | ID: mdl-34882588
BACKGROUND: Patients with early-onset scoliosis (EOS) and spasticity may receive treatment with an intrathecal baclofen pump. We assessed how baclofen pumps are associated with the odds of complications and secondary interventions after growth-friendly (GF) spine surgery for EOS and analyzed infectious complications within the pump cohort. METHODS: Using a prospectively maintained, international multicenter database, we studied patients with neuromuscular EOS with baclofen pumps who underwent GF spine surgery from 2002 through 2019 (n=25). Baclofen pumps were implanted before GF instrumentation in 18 patients, during in 2 patients, and after in 5 patients. Patients with existing pumps at initial GF spine surgery were matched 1:3 with 54 patients (control group) without pumps according to treatment center, year of surgery, diagnosis, surgery type, and preoperative curve magnitude. Univariate analysis and multivariate logistic regression were performed to compare complications and secondary interventions between the 2 cohorts. RESULTS: Patients with baclofen pumps had 4.8 times the odds [95% confidence interval (CI): 1.5-16] of experiencing any complication within 1 year after initial GF spine surgery compared with controls. During mean follow-up of 6.9±4.3 years, they had 4.7 times the odds (95% CI: 1.3-16) of deep surgical site infection and 5.6 times the odds (95% CI: 1.2-26) of spinal rod removal after any complication. Differences in rates of mechanical complication, such as rod migration and breakage, were nonsignificant between the 2 groups. For the 9 patients (50%) with pumps who experienced infections, the most common microorganisms were Staphylococcus aureus (4 patients) and Pseudomonas aeruginosa (2). The pump/catheter was revised or removed, in addition to antibiotic therapy or surgical irrigation and debridement, in 2 patients. CONCLUSIONS: Among patients with neuromuscular EOS, those with baclofen pumps are much more likely to experience complications within 1 year after GF spine surgery. They are also more likely to have deep surgical site infections, with S. aureus and P. aeruginosa being the most common causative organisms, and to require spinal rod removal. LEVEL OF EVIDENCE: Level III-retrospective comparative study.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Escoliosis / Fusión Vertebral / Relajantes Musculares Centrales Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Pediatr Orthop Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Escoliosis / Fusión Vertebral / Relajantes Musculares Centrales Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Pediatr Orthop Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos